219 related articles for article (PubMed ID: 17009963)
1. Clinical application of oxaliplatin in epithelial ovarian cancer.
Fu S; Kavanagh JJ; Hu W; Bast RC
Int J Gynecol Cancer; 2006; 16(5):1717-32. PubMed ID: 17009963
[TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin salvage for recurrent ovarian cancer: a single institution's experience in patient populations with platinum resistant disease or a history of platinum hypersensitivity.
Taylor SE; Beck TL; Krivak TC; Zorn KK; Kelley JL; Edwards RP
Gynecol Oncol; 2014 Jul; 134(1):68-72. PubMed ID: 24769036
[TBL] [Abstract][Full Text] [Related]
3. Oxaliplatin-based combination chemotherapy is still effective for the treatment of recurrent and platinum-resistant epithelial ovarian cancer: results from a single center.
Zhang G; Li XP; Liu BJ; Wang JL; Wang SJ; Cui H; Wei LH
Chin Med J (Engl); 2013 Dec; 126(23):4477-82. PubMed ID: 24286410
[TBL] [Abstract][Full Text] [Related]
4. Oxaliplatin: a review of preclinical and clinical studies.
Raymond E; Chaney SG; Taamma A; Cvitkovic E
Ann Oncol; 1998 Oct; 9(10):1053-71. PubMed ID: 9834817
[TBL] [Abstract][Full Text] [Related]
5. Oxaliplatin for the treatment of ovarian cancer.
Bogliolo S; Cassani C; Gardella B; Musacchi V; Babilonti L; Venturini PL; Ferrero S; Spinillo A
Expert Opin Investig Drugs; 2015; 24(9):1275-86. PubMed ID: 26125301
[TBL] [Abstract][Full Text] [Related]
6. Oxaliplatin-based chemotherapy in the management of colorectal cancer.
Capdevila J; Elez E; Peralta S; Macarulla T; Ramos FJ; Tabernero J
Expert Rev Anticancer Ther; 2008 Aug; 8(8):1223-36. PubMed ID: 18699761
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin in practice.
Misset JL
Br J Cancer; 1998 Jun; 77 Suppl 4(Suppl 4):4-7. PubMed ID: 9647612
[TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.
Culy CR; Clemett D; Wiseman LR
Drugs; 2000 Oct; 60(4):895-924. PubMed ID: 11085200
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine in epithelial ovarian cancer treatment: current role and future perspectives.
Lorusso D; Ferrandina G; Fruscella E; Marini L; Adamo V; Scambia G
Int J Gynecol Cancer; 2005; 15(6):1002-13. PubMed ID: 16343176
[TBL] [Abstract][Full Text] [Related]
10. [Oxaliplatin: the first DACH platinum in clinical practice].
Soulié P; Raymond E; Brienza S; Cvitkovic E
Bull Cancer; 1997 Jun; 84(6):665-73. PubMed ID: 9295871
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy for ovarian cancer: an evidence-based approach.
Geisler JP; Manahan KJ; Wiemann MC
Minerva Ginecol; 2004 Dec; 56(6):539-45. PubMed ID: 15729206
[TBL] [Abstract][Full Text] [Related]
12. Role of chemotherapy in epithelial ovarian cancer.
Markman M
Minerva Ginecol; 2011 Jun; 63(3):287-97. PubMed ID: 21654613
[TBL] [Abstract][Full Text] [Related]
13. Oxaliplatin in first-line therapy for advanced non-small-cell lung cancer.
Raez LE; Kobina S; Santos ES
Clin Lung Cancer; 2010 Jan; 11(1):18-24. PubMed ID: 20085863
[TBL] [Abstract][Full Text] [Related]
14. [Oxaliplatin and ovarian cancer].
Dieras V; Girre V; Guilhaume MN; Laurence V; Mignot L
Bull Cancer; 2006 Feb; 93 Suppl 1():S35-9. PubMed ID: 16483943
[TBL] [Abstract][Full Text] [Related]
15. Is single-agent chemotherapy acceptable in platinum-sensitive relapsed ovarian cancer?
Abou-Jawde RM; Oberoi SS
J Clin Oncol; 2008 May; 26(15):2602-3; author reply 2603. PubMed ID: 18487582
[No Abstract] [Full Text] [Related]
16. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer.
Chollet P; Bensmaïne MA; Brienza S; Deloche C; Curé H; Caillet H; Cvitkovic E
Ann Oncol; 1996 Dec; 7(10):1065-70. PubMed ID: 9037366
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group study.
Fracasso PM; Blessing JA; Morgan MA; Sood AK; Hoffman JS
J Clin Oncol; 2003 Aug; 21(15):2856-9. PubMed ID: 12885801
[TBL] [Abstract][Full Text] [Related]
18. Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
Swisher EM; Mutch DG; Rader JS; Elbendary A; Herzog TJ
Gynecol Oncol; 1997 Sep; 66(3):480-6. PubMed ID: 9299264
[TBL] [Abstract][Full Text] [Related]
19. Prospective evaluation of weekly topotecan in recurrent platinum-resistant epithelial ovarian cancer.
Le T; Hopkins L; Baines KA; Rambout L; Fung-Kee-Fung M
Int J Gynecol Cancer; 2008; 18(3):428-31. PubMed ID: 17692088
[TBL] [Abstract][Full Text] [Related]
20. Oxaliplatin in ovarian cancer.
Sessa C; ten Bokkel Huinink WW; du Bois A
Ann Oncol; 1999; 10 Suppl 1():55-7. PubMed ID: 10219454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
